
PRME Stock Forecast & Price Target
PRME Analyst Ratings
Bulls say
Prime Medicine Inc is positioned for substantial growth, with projections indicating risk-adjusted revenues from its PM577 program escalating from $32 million in 2030 to $980 million by 2035, highlighting a robust future revenue stream driven by its innovative Prime Editing technology. The company’s advancing pipeline, particularly in Wilson's Disease and its in vivo gene editing efforts, aligns with significant unmet medical needs and showcases a high likelihood of technical success based on strong preclinical data. Furthermore, anticipated positive readouts from ongoing trials could enhance investor interest and confidence in Prime Medicine's transformative capabilities within the gene editing landscape.
Bears say
The analysis highlights several fundamental concerns regarding Prime Medicine Inc.'s stock outlook, particularly relating to regulatory approval and clinical trial recruitment challenges. The potential for downward revisions in projections exists if the company struggles to gain regulatory approval for its products, especially if the regulatory pathway proves more complex than anticipated. Additionally, pricing concerns regarding the market's ability to absorb the cost of Prime's therapies, alongside safety risks associated with gene editing technology, further underpin a negative outlook on the company's financial stability and growth prospects.
This aggregate rating is based on analysts' research of Prime Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.
PRME Analyst Forecast & Price Prediction
Start investing in PRME
Order type
Buy in
Order amount
Est. shares
0 shares